A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of Curene® Versus Placebo In Reducing Symptoms Of Knee OA
Notes for this study:
||(mg/dl). Within group. Placebo: before 0.72±0.26, after 0.73±0.24. Intervention: beofre 0.75±0.22, after 0.83±0.15
|Number of Subjects
||30-44, 45-64, 65+
||Obese, Overweight, Average, Underweight
In a randomized, double-blind, placebo-controlled trial, 50 patients with knee osteoarthritis were assigned to take 500 mg (>20% total curcuminoids) of a novel, highly bioavailable turmeric extract for 60 days.
Funding issues for this study:
The primary outcome was a global score of osteoarthritis symptoms (WOMAC). The turmeric group saw a large, statistically significant improvement in all osteoarthritis symptoms compared with placebo, The turmeric extract group also saw a large and statistically significant reduction in pain compared with the placebo group, as measured by a visual analog scale.
There was no noted difference in the rate of adverse events between groups, and the rate was low for both. The group that received the turmeric extract began to take less pain medication than the placebo group.
"The research was funded by Olene Life Sciences Private Limited, Chennai, which manufactures Curene®. Neither the funding agency nor any outside organization has participated in study design or have any conflicts of interest. Olene life Sciences had final approval of the manuscript."